anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
Viral hepatitis are primarily human systemic infections caused by viruses hepatic diseases which cause damage to the liver by hepatocyte infection of the virus and/or a host immune response to the virus. (1) Hepatitis is grouped into five types (A, B, C, D, E) and is mainly transmitted by parenteral, sexual and fetomaternal. (2) Hepatitis B virus (HBV) was discovered in 1965 in the United States.(3)It is a DNA virus that belongs to the family Hepadnaviridae. (4) Hepatitis B infection is characterized by signs clinical conditions such as jaundice, asthenia, anorexia but in the vast majority of cases (98% of infections). The course of hepatitis B is not serious; Nine out of ten people will clear the virus thanks to their immune defenses: they heal spontaneously and are immune because they made antibodies against HBV.(5) In 10% of infected people (15% in men, 5% in women), the hepatitis virus B will remain in the liver where it will be more or less active. This activity leads to chronic hepatitis.

Approximately 316 million people are chronic carriers of HBV worldwide (1-3) and approximately 887,000 deaths are linked to the hepatitis B virus each year. Appropriate support for carrying Chronic HBV reduces the risk of transmission. The WHO has set the goal of elimination of viral hepatitis B and C in 2030.(5) The biomarkers specifically associated with this infection are: Hbs antigen (HbsAg), antibodies anti-Hbs, anti-HBc antibodies, Hbe antigen, anti-HBe antibodies, virus DNA in plasma.

Chronic hepatitis B is defined by the maintenance of HBs antigen in the blood beyond 6 months.(6) The diagnosis of acute hepatitis B is based on the combination of a clinical picture such as acute febrile state.

accompanied or followed by jaundice or an increase in hepatic transaminases (AST, ALT, gammaGT) and the presence of HBs antigen and anti-HBc IgM and viral DNA in the blood.(6) Treatment monitoring of chronic hepatitis B is carried out by monitoring the viral load of hepatitis B in the blood. Furthermore, quantification of viral load during hepatitis monitoring Chronic B is essential in order to be able to assess and anticipate the risk of progression towards fibrosis.(6) On the European market, quantitative determination of hepatitis B viral load as part of Diagnosis and monitoring of the disease is done by real-time PCR which is the reference technique.(7) As part of routine care, there are several diagnostic PCR kits that can be used on plasma or serum. Today, there are no CE approved PCR kits that allow the quantification of viral DNA at the both serum and plasma. Our study will make it possible to evaluate the performance of the Bioneer kit PCR kit AccuPower® Quant Kit Bioneer ExiStation™FA 96/384 on serum and plasma from patients with hepatitis B.
Dabrafenib is an inhibitor of some mutated forms of BRAF kinases with in vitro IC50 values of 0.65, 0.5, and 1.84 nM for BRAF V600E, BRAF V600K, and BRAF V600D enzymes, respectively. Dabrafenib also inhibits wild-type BRAF and CRAF kinases with IC50 values of 3.2 and 5.0 nM, respectively, and other kinases, such as SIK1, NEK11, and LIMK1 at higher concentrations. Some mutations in the BRAF gene, including those that result in BRAF V600E, can result in constitutively activated BRAF kinases that may stimulate tumor cell growth [see Indications and Usage (1)]. Dabrafenib inhibits cell growth of various BRAF V600 mutation-positive tumors in vitro and in vivo.

Dabrafenib and trametinib target two different kinases in the RAS/RAF/MEK/ERK pathway. Use of dabrafenib and trametinib in combination resulted in greater growth inhibition of BRAF V600 mutation-positive tumor cell lines in vitro and prolonged inhibition of tumor growth in BRAF V600 mutation-positive tumor xenografts compared with either drug alone.

In the setting of BRAF-mutant colorectal cancer, induction of EGFR-mediated MAPK pathway re-activation has been identified as a mechanism of intrinsic resistance to BRAF inhibitors [see Indications and Usage (1.8)].
The sham group will receive sham olfactory enrichment sessions, which is designed with the same pattern (twice a day, 30 min for each session, on preoperative day 1-3 and on postoperative day 1-3. The only difference is that there is no odor in the device. Water will be used in the dispenser.
The invention discloses a deodorizing traditional Chinese medicine composition, a preparation method and application thereof, and belongs to the technical field of traditional Chinese medicine insoles. The monarch and ministerial drugs in the composition are folium Artemisiae Argyi, Poria, flos Caryophylli, Borneolum Syntheticum and herba Artemisiae Annuae; the adjuvant and guiding drugs include Perillae herba, ramulus Cinnamomi, herba asari, herba Erodii seu Geranii, radix Clematidis, herba Moslae, herba Morii Pilossi, Atractylodis rhizoma, spina Gleditsiae, semen Vaccariae, radix et rhizoma Rhei, fructus Schisandrae, radix Gentianae Marcrophyllae, herba Agastaches, Alumen, radix Angelicae Pubescentis, herba Ephedrae, cimicifugae rhizoma and herba Siegesbeckiae. The deodorant Chinese medicinal preparation has effects of eliminating dampness, removing toxic substances, relieving inflammation, killing bacteria, enhancing resistance, improving immunity, regulating yin and yang balance, and relieving cold womb. The prescription is made into insole, and the user can absorb Chinese medicinal components through sole skin, reach focus of infection through drug effect, so as to regulate body, and has no side effect on human body. The insole has no odor. The insole containing the formula is suitable for patients with tinea pedis, foot odor, tinea pedis, cold limbs, cold womb, prostatitis, blood circulation disorder, and deficiency of both yin and yang.
Part B participants received romiplostim 750 µg subcutaneously (SC) once weekly (QW) for 8 weeks. Participants who complete Part B could continue to receive weekly injections of romiplostim for up to 1 year in the extension treatment phase.
Techniques are described for a non-invasive detection of a health condition of an organ. In an example, the electrical conductivity of the organ reflects the organ's health of. An inductive damping sensor can be used to detect the organ's electrical conductivity and, thus, its health. The inductive damping sensor can be placed in proximity of the organ such as the organ is within the magnetic field generated based on a coil of the inductive damping sensor. The conductivity of the organ impacts the inductance and the resistance of the coil. Hence, the inductance and/or resistance of the coil can be measured, where the measurements can be associated with the health of the organ.
The invention discloses a powder of coarse cereals for the treatment of hyphemia, wherein each 100kg of the powder comprises the constituents of coix seed 20kg, Chinese sorghum 15kg, peanut 12kg, maize, buckwheat, millet, wheat each 10kg, red bean, black soybean each 5kg, soybean 3kg. In spring and summer, the mung bean can be used for substituting red bean. The preparing process of the powder comprises the steps of refining each composition and cleaning, drying, disintegrating, mixing homogeneously according to proportion, finally carrying out packaging as requirement. The powder contains rich natural vitamins, dietary fiber and microelements needed by human bodies. The powder has the effects of balancing nourishment and enhancing immunological functions. The invention also discloses the method for eating the coarse cereal powder.
Osteoarthritis (OA) is a common joint disease affecting 1 in 10 Canadians. Osteoarthritis commonly presents in the knee joint and is associated with mobility limitations, pain, and an increased risk of other chronic health conditions such as heart disease. It is critical to implement exercise for people with knee OA as it can be an effective method for improving pain, mobility, and cardiovascular health. A biomechanical exercise program using static yoga postures has been established in the investigators lab based on minimizing damaging knee joint loads, while effectively exercising the musculature around the knee joint. The investigators pilot project (REB#13-510) showed that a 12-week yoga program using these biomechanical exercises improved pain and mobility while keeping the medial joint loading well below that experienced during normal level walking. The next step with this exercise program is to compare clinical and tissue outcomes with that of a regularly prescribed aerobic and strengthening program, as well as a control group completing meditation classes. The investigators aim to identify differences in clinical mobility performance outcomes, muscle and fat volumes using magnetic resonance imaging (MRI), and cartilage integrity using MRI between the three groups using a randomized controlled trial (RCT) design.
INTRODUCTION: Acute undifferentiated febrile illnesses (AUFIs) impose a large burden in the tropics. Understanding of AUFI's epidemiology is limited. Insufficient diagnostic capacity hinders the detection of outbreaks. The lack of interconnection in healthcare systems hinders timely response. We describe a protocol to study the epidemiology and aetiologies of AUFI and pathogen discovery in strategic areas of Latin America (LA).
METHODS AND ANALYSIS: Global Infectious Diseases Network investigators comprising institutions in Colombia, Dominican Republic, México, Perú and the USA, developed a common cohort study protocol. The primary objective is to determine the aetiologies of AUFI at healthcare facilities in high-risk areas. Data collection and laboratory testing for viral, bacterial and parasitic agents are performed in rural and urban healthcare facilities and partner laboratories. Centralised laboratory and data management cores deploy diagnostic tests and data management tools. Subjects >6 years with fever for <8 days without localised infection are included in the cohort. They are evaluated during the acute and convalescent phases of illness. Study personnel collect clinical and epidemiological information. Blood, urine, nasal or pharyngeal swabs and saliva are collected in the acute phase and blood in convalescent phase. Specimens are banked at -80°C. Malaria, dengue and COVID-19 are tested onsite in the acute phase. The acute-phase serum is PCR tested for dengue, chikungunya, Venezuelan equine encephalitis, Mayaro, Oropouche, Zika, and yellow fever viruses. Paired convalescent and acute serum antibody titters are tested for arbovirus, Leptospira spp, and Rickettsia spp. Serum is used for viral cultures and next-generation sequencing for pathogen discovery. Analysis includes variable distributions, risk factors and regression models. Laboratory results are shared with health authorities and network members.
ETHICS AND DISSEMINATION: The protocol was approved by local ethics committees and health authorities. The results will be published in peer-reviewed journals. All study results are shared with local and regional health authorities.
PURPOSE: A Ribes fasciculatum var. chinense extract is provided to alleviate dermatitis symptom, to reduce plasma IgE, and TNF-alpha and IL-6 in macrophage, to suppress histamine release, and to be used as a pharmaceutical composition or a cosmetic composition for preventing and treating atopic dermatitis. CONSTITUTION: An external use skin composition for preventing and treating atopic dermatitis contains 0.1-50 wt% of a Ribes fasciculatum var. chinense extract as an active ingredient. A pharmaceutical composition is manufactured in the form of a cream, a gel, a patch, a spray, an ointment, a plaster, a lotion, a liniment, a paste, or a cataplasma. The extract is prepared using water including purified water, C1-C4 alcohol, or a mixture thereof. A cosmetic composition for preventing and treating atopic dermatitis contains the extract as an active ingredient.
AV Delay Optimised RV Pacing. Subjects will remain in this arm for 3 months before being crossed-over.
BACKGROUND: Dilated cardiomyopathy (DCM) involves myocardial remodeling, characterized by significant fibrosis and extracellular matrix expansion. These changes impair heart function, increasing the risk of heart failure and sudden cardiac death. This study investigates the prognostic value of circulating fibrosis biomarkers as a less invasive method in DCM patients.
METHODS: Plasma samples from 185 patients with confirmed DCM were analyzed to measure 13 circulating biomarkers using Luminex bead-based multiplex assays and ELISA. The prognostic value of these biomarkers was evaluated concerning heart failure-associated events and all-cause mortality.
RESULTS: Elevated MMP-2 levels (>1519.3 ng/mL) were linked to older age, higher diabetes prevalence, lower HDL, increased NT-proBNP and hs-TnT levels, and severe systolic dysfunction. High TIMP-1 levels (>124.9 ng/mL) correlated with elevated NT-proBNP, more atrial fibrillation, reduced exercise capacity, and larger right ventricles. Increased GDF-15 levels (>1213.9 ng/mL) were associated with older age, systemic inflammation, renal impairment, and poor exercise performance. Elevated OPN levels (>81.7 ng/mL) were linked to higher serum creatinine and NT-proBNP levels. Over a median follow-up of 32.4 months, higher levels of these biomarkers predicted worse outcomes, including increased risks of heart failure-related events and mortality.
CONCLUSIONS: Circulating fibrosis biomarkers, particularly MMP-2, TIMP-1, GDF-15, and OPN, are valuable prognostic tools in DCM. They reflect the severity of myocardial remodeling and systemic disease burden, aiding in risk stratification and therapeutic intervention. Integrating these biomarkers into clinical practice could improve DCM management and patient prognosis.
OBJECTIVE: This study aims to explore the relationship between pre-existing renal impairment and oncological outcomes in upper tract urothelial carcinoma (UTUC) patients treated with radical nephroureterectomy (RNU) using data from a multicentre international registry.
PATIENTS AND METHODS: Data on non-metastatic UTUC patients who underwent RNU were obtained from the Clinical Research Office of the Endourology Society Urothelial Carcinomas of the Upper Tract (CROES-UTUC) Registry. Patients were categorised into normal pre-operative renal function and chronic renal impairment (CKD) groups, with CKD defined as an estimated glomerular filtration rate below 60 mL/kg/1.73 m². Kaplan-Meier survival analysis was employed to investigate disease-free survival (DFS) and overall survival (OS). Multivariable Cox regression analysis was conducted to identify confounding variables.
RESULTS: A total of 1393 patients diagnosed with UTUC who underwent RNU between 2014 and 2019 were analysed. 875 patients (62.4%) had normal renal function, whilst 528 patients (37.6%) had CKD prior to RNU. The two groups had similar proportions of bladder cancer history, comparable cardiovascular comorbidity, similar tumour stage, and comparable proportions receiving laparoscopic or robotic-assisted RNU. In multivariable cox regression analysis, CKD was found to be associated with inferior DFS (HR = 1.419; 95%CI = 1.060-1.898; p = 0.019). Upon multivariable analysis, pre-existing renal impairment and higher T stage (HR = 4.613; 95%CI = 1.829-4.712; p < 0.001) and the use of adjuvant chemotherapy (HR = 1.858; 95%CI = 1.229-2.807; p = 0.003) were also found to associate with worse DFS. Significant cardiovascular disease and higher T stage were associated with worse OS. Existing renal impairment at baseline did not have any significant associated with OS.
CONCLUSION: In this multicentre registry, preoperative chronic renal impairment was identified as an independent predictor of inferior DFS in patients undergoing RNU for non-metastatic UTUC. Preoperative CKD could serve as a clinical predictor of poorer oncological outcomes.
The motion sickness is a disease which possesses clinical manifestations of dizziness, vertigo, nausea, vomit, pale complexion, cold sweating and the like by vestibule and vegetative nerve when people takes vehicles. The motion sickness comprises the carsickness, seasickness, airsickness and space sickness. The invention relates to a compound perilla slow release motion sickness resistance medicinal membrane formula and its preparation method. The formula has the advantages of good contact surface with acupuncture point, small side-effect, long effect time, convenient administration and high medicine utilization rate. The preparation method comprises the following steps: selecting three chemical components for respectively feeding experimental animals, carrying out simulated motion, screening optimum composition possessing prevention effect, preparing a three-dimensional net-like support by a soft substrate auxiliary material and taking as a carrier, and filling a medicine extract in the three-dimensional net-like support to prepare to a thin film shape. The product pasted on the acupuncture point is capable of performing slow decomposition with the carrier, and the effective components enable slow release, so that the effective effect time of the medicine can be prolonged.
This study will enroll persons with opioid use disorder (N=120) who have recent fentanyl exposure (as assessed via urinalysis testing). Participants will be randomized to receive suvorexant or placebo for the duration of the study enrollment, which will serve as the between-groups experimental comparison. The study will consist of a brief (5 day) residential phase and 3-week outpatient phase. During the residential phase, all participants will be briefly maintained on a short acting opioid prior to induction onto sublingual (SL) buprenorphine (using either the buprenorphine or buprenorphine/naloxone product). At the end of the 5-day residential period, participants will be discharged to complete the \~3-week outpatient phase. During the outpatient period all participants will be maintained on SL buprenorphine/naloxone and continue to receive suvorexant or placebo, and at the end of the study participants will receive an injection of XR-buprenorphine (Sublocade). All buprenorphine procedures will be open label and will follow standard-of-care practices. Study medication during the outpatient period will be managed using an automated pill dispenser. Data collection will consist of forehead-based EEG monitoring, wrist-worn actigraphy/photoplethysmography, and questionnaires delivered during study visits or via cell-phone based ecological momentary assessments.
Prepn. of human immune response suppressor (hIRS) is effected by multiplication of human derived hIRS producing cell with transplantation into warm-blooded animal except human, or with supply of the animal's body fluid, and producing hIRS from the obtd. cell. hIRS inducer is used at the producing hIRS. hIRS is used as drug for allergic and autoimmune diseases, and anaphylaxie shock and as inhibitor for immuno rejection at transplantation. This prepn. gives stable and fast multiplication without expensive medium, with easy control.
Adults (21 y.o. and older) who smoke ate least 10 non-menthol cigarettes per day will be recruited.
Arm 1: Control 'step-up' therapy in the cohort (MONITOR-PsA study). Therapy for the cohort is defined by standard practice in these PsA clinics following current international recommendations and National requirements for the prescription of biologic therapy. Whilst physician discretion is used, most commonly Initial therapy will be with methotrexate alone (15mg/week rising to 25mg/week as tolerated by week 8 of therapy) unless this is contraindicated. In cases of non-response or intolerance to methotrexate, participants will have an alternative DMARD (most commonly sulfasalazine or leflunomide) added or switched to at the discretion of the rheumatologist. In cases of failure of two DMARDs, treatment can be escalated to biologic therapy as per National Institute for Health and Clinical Excellence (NICE) recommendations usually with a TNF inhibitor as first line. If the requisite disease activity is not met or if there are contraindications to biologics, alternative DMARD combinations will be used. Further details are available in the PsA clinic treatment protocol which is Appendix D in the MONITOR-PsA protocol.

Arm 2: Symptomatic therapy arm. The intervention will delay standard treatment with disease-modifying anti-rheumatic drugs (DMARDs) and use local glucocorticoid injections to affected joints instead. Oral non-steroidal anti-inflammatory drugs (NSAIDs) will also be allowed as concomitant medication as indicated for individuals. Local glucocorticoid injections will include injections with methylprednisolone or triamcinolone. All active joints will be treated with glucocorticoid injections. Glucocorticoid injections can be either be given as an intra-articular injection to an inflamed joint or as an intra-muscular injection if multiple joints are involved. If any joint requires more than 2 local injections of glucocorticoid within a 6 month period, then the patient is deemed to have failed symptomatic therapy and will be withdrawn from the treatment protocol and be treated as per usual care (in most cases with DMARD therapy). If Participants require DMARD therapy, they will be offered rescue therapy as per usual clinical care but will be asked to continue with data collection for the trial. This is to ensure that sufficient data is collected for the trial but risks in delaying treatment to the individual are mitigated.
Subjects will receive a reduced-calorie low energy density diet which will provide 85% of their energy needs for a period of 4 weeks. To have a condition of energy restriction without CDR, they will not be told that they are on a low-calorie diet and non-restrictive messages will be used.
In Period 1 on Day 1, participants will receive ABBV-903 Tablet Form 1 after fasting. In Period 2 on Day 1, participants will receive ABBV-903 Tablet Form 2 after fasting. Lastly, in Period 3 on Day 1, participants will receive ABBV-903 Tablet Form 1 after a high fat meal. Participants will be followed up for 30 days.
Procaine-penicillin G is prepared in a form suitable for the extemporaneous preparation of an aqueous suspension, by coating particles of the procaine-penicillin G at least in part with at least one monoaminomonophospholipid, particularly a - and b -lecithin, a - and b -cephalin, partially hydroxtlated lecithin or cephalin, and mixtures thereof in the proportions of 1 to 10 per cent, and preferably 7.4 per cent, by weight.  The particle size of the coated procaine-penicillin G is sufficiently small to pass a 60-mesh B.S.S. sieve.  According to the example, a partially hydroxylated soyabean lecithin-cephalin monoaminomonophospholipid mixture is dissolved in chloroform, the solution sterilized by filtration through a Leitz filter pad, the sterile solution mixed under sterile conditions with sterile powdered procaine-penicillin G and the coated particles produced by removing the solvent under reduced pressure at a temperature below 50 DEG  C., are milled to pass a 60-mesh sieve. The powder may be stored in sterile bottles and, when required, may be suspended in water or normal saline solution by shaking.  Other organic solvents boiling below 100 DEG  C., such as petroleum ether and carbon tetrachloride, may be used in place of the chloroform.